AG
CRVS icon

Algert Global’s Corvus Pharmaceuticals CRVS Stock Holding History

Algert Global’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-14,949
Closed -$72K – 998
2021
Q3 		$72K Sell
14,949
-4,788
-24% -$14.2K 0.01% 989
2021
Q2 		$53K Sell
19,737
-23,120
-54% -$63.7K 0.02% 411
2021
Q1 		$132K Buy
42,857
+27,390
+177% +$98.9K 0.04% 396
2020
Q4 		$55K Buy
15,467
+4,220
+38% +$17K 0.02% 393
2020
Q3 		$45K Buy
+11,247
New +$44.9K 0.01% 379
2020
Q2 		– Sell
-16,947
Closed -$36K – 436
2020
Q1 		$36K Buy
+16,947
New +$68.8K 0.02% 387

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Algert Global's CRVS Position: Q4 2021 in Review

Algert Global sold out of Corvus Pharmaceuticals (CRVS) in Q4 2021, closing a stake of 14,949 shares — an estimated $72K sold.

Algert Global first reported a position in CRVS in Q1 2020 and held it in 6 quarters. The position peaked at $132K in Q1 2021. 62 funds tracked by Wall St. Rank hold CRVS as of Q4 2021.

  • Algert Global reported no remaining Corvus Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Algert Global sold 14,949 Corvus Pharmaceuticals shares in Q4 2021, an estimated $72K.
  • Algert Global first reported a position in Corvus Pharmaceuticals in Q1 2020 and held it in 6 quarters.
  • Algert Global's Corvus Pharmaceuticals position peaked at $132K in Q1 2021.
  • 62 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q4 2021.

Based on Algert Global's 13F filing for Q4 2021, filed 14 Feb 2022.